Neoadjuvant chemotherapy can be effective in surgically downstaging HR-positive, HER2-negative breast cancers; however, pathological complete response is uncommon, though more frequently observed in young patients and/or those with high-grade tumours [14]. This evidence concerns the gene ERBB2 and neoplasm.